N N Kolesnikov,Yu A Veryaskina,S E Titov et al.
N N Kolesnikov et al.
Background: It is shown that each type of human malignancies has a unique set of expressed miRNAs, and tumor-specific miRNAs in biological tissues of a patient are stable. The aim of this study was to determine the differ...
Trainees' knowledge and application of guideline recommendations for colorectal cancer screening and surveillance [0.03%]
结直肠癌筛查和监测指南推荐的学员知识和应用能力研究
Rushad Patell,Abhishek Karwa,Rocio Lopez et al.
Rushad Patell et al.
Background: Data shows that practicing physicians don't recommend colorectal (CRC) screening and surveillance as suggested by guidelines. We assessed knowledge of CRC guidelines in medical trainees. ...
Ingegerd Hellstrom,Yuen Yee Yip,Martin Darvas et al.
Ingegerd Hellstrom et al.
Background: The gene encoding HE4 undergoes alternative splicing to yield multiple protein isoforms. We investigated anti-HE4 mAbs which recognize epitopes on the C (2H5 and 3D8) or N (12A2 and 14E2) terminals. ...
Evaluation of body Computed Tomography-determined sarcopenia in breast cancer patients and clinical outcomes: A systematic review [0.03%]
乳腺癌患者身体计算机断层扫描测定的肌肉减少症与临床结局的系统评价
Federica Rossi,Francesca Valdora,Bianca Bignotti et al.
Federica Rossi et al.
Purpose: Sarcopenia has been considered a poor prognostic factor in various malignant diseases. However, the studies that evaluated the association between CT-determined sarcopenia and outcome in breast cancer patients re...
Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer [0.03%]
去势抵抗性前列腺癌患者血清标志物与肝转移灶容积之间的关系
Lahiru Ranasinghe,Patrick Cotogno,Elisa Ledet et al.
Lahiru Ranasinghe et al.
Background: Prostate cancer patients with liver metastases have a poor prognosis. To date, no study exists investigating the relationship between liver tumor burden and clinical laboratory markers. ...
A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer [0.03%]
二项二期临床试验合并分析：二甲双胍联合以铂类为基础的化疗用于晚期非小细胞肺癌患者
Anish B Parikh,Kristen A Marrone,Daniel J Becker et al.
Anish B Parikh et al.
Background: Despite a wealth of preclinical and observational data, prospective data regarding the use of metformin in lung cancer is extremely limited. M...
ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: A clinical perspective [0.03%]
一项关于携带食物服用塞瑞替尼450mg的ALK阳性非小细胞肺癌患者药代动力学、安全性和有效性的ASCEND-8临床试验数据解读
Salman Otoukesh,Tiffany Sanchez,Saied Mirshahidi et al.
Salman Otoukesh et al.
Anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) is diagnosed in up to 126,000 patients worldwide annually. Ceritinib is a next-generation ALK-targeted tyrosine kinase inhibitor that is approved for the treatmen...
Economic disparities in Appalachia linked to risk factors for long-term health for estrogen positive breast cancer patients [0.03%]
美国阿巴拉契亚地区的经济差异与雌激素受体阳性乳腺癌患者长期健康风险因素有关
Patricia N E Roberson,Melanie Miller,Jillian Lloyd et al.
Patricia N E Roberson et al.
Background: Breast cancer is the second leading cause of cancer death for women in the United States and mortality from cancer is more common among individuals in the Appalachian region compared to the rest of the country...
Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes [0.03%]
晚期非小细胞肺癌住院和门诊患者的特征及结局
Joanna Gotfrit,Caleb Jonker,Tinghua Zhang et al.
Joanna Gotfrit et al.
Background: Most newly diagnosed advanced NSCLC patients have an initial medical oncology consult as an outpatient. Sometimes, the initial consult occurs as an inpatient. We explored differences among NSCLC patients prese...
Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma [0.03%]
基线血浆IL-6升高可预测索拉非尼治疗转移性透明细胞型肾癌患者的疗效欠佳
Martin Pilskog,Gry Hilde Nilsen,Christian Beisland et al.
Martin Pilskog et al.
Introduction: Clear cell renal cell carcinoma (ccRCC) is the most common type among renal cell carcinomas, and anti-angiogenic treatment is currently first line therapy in metastatic ccRCC (mccRCC). Response rates and dur...